Vaxil Bio arranges $350,000 private placement

Executive Summary

• Vaxil Bio Ltd. announced a non-brokered private placement of up to 2,456,140 units at 14.25 cents per unit, aiming to raise gross proceeds of up to $350,000.
• Each unit consists of one common share and one common share purchase warrant, with warrants exercisable at 19 cents per share for five years.
• Net proceeds are designated for general corporate purposes, with the offering expected to close around November 14, 2025, subject to TSX Venture Exchange approval.

Key Details

• Offering Size: Up to 2,456,140 units.
• Price: 14.25 cents per unit.
• Gross Proceeds: Up to $350,000.
• Unit Composition: One common share and one common share purchase warrant per unit.
• Warrant Terms: Exercisable at $0.19 per share; valid for five years following closing.
• Use of Proceeds: General corporate purposes.
• Finder’s Fees: Cash commission of up to 8% of gross proceeds and non-transferable warrants equal to up to 8% of the aggregate number of units issued.
• Hold Period: Four months and one day from the date of issue for units, shares, and warrants.
• Closing Conditions: Subject to approval by the TSX Venture Exchange.
• Expected Closing Date: On or around November 14, 2025.

Notable Quotes

• None provided in the text.